Zobrazeno 1 - 10 of 166 pro vyhledávání: '"Kuvalekar M"'
1
Akademický článek
Phenotypic and functional characterization of posoleucel, a multivirus-specific T cell therapy for the treatment and prevention of viral infections in immunocompromised patients.
Autor: Vasileiou S; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston, TX; AlloVir, Inc., Waltham, MA., Kuvalekar M; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston, TX; AlloVir, Inc., Waltham, MA., Velazquez Y; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston, TX; AlloVir, Inc., Waltham, MA., Watanabe A; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston, TX., Leen AM; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston, TX; AlloVir, Inc., Waltham, MA., Gilmore SA; AlloVir, Inc., Waltham, MA. Electronic address: sgilmore@allovir.com.
Publikováno v: Cytotherapy [Cytotherapy] 2024 Aug; Vol. 26 (8), pp. 869-877. Date of Electronic Publication: 2024 Mar 19.
Zobrazit plný text záznamu
2
Akademický článek
T cell immune profiling of respiratory syncytial virus for the development of a targeted immunotherapy.
Autor: Papayanni PG; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston, Texas, USA., Koukoulias K; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston, Texas, USA., Kuvalekar M; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston, Texas, USA., Watanabe A; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston, Texas, USA., Velazquez Y; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston, Texas, USA., Ramos CA; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston, Texas, USA., Leen AM; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston, Texas, USA., Vasileiou S; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston, Texas, USA.
Publikováno v: British journal of haematology [Br J Haematol] 2023 Aug; Vol. 202 (4), pp. 874-878. Date of Electronic Publication: 2023 Jun 15.
Zobrazit plný text záznamu
4
Akademický článek
Targeting IDH2R140Q and other neoantigens in acute myeloid leukemia.
Autor: Leung WK; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital, and Houston Methodist Hospital, Houston, TX., Torres Chavez AG; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital, and Houston Methodist Hospital, Houston, TX., French-Kim M; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital, and Houston Methodist Hospital, Houston, TX., Shafer P; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital, and Houston Methodist Hospital, Houston, TX., Mamonkin M; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital, and Houston Methodist Hospital, Houston, TX., Hill LC; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital, and Houston Methodist Hospital, Houston, TX., Kuvalekar M; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital, and Houston Methodist Hospital, Houston, TX., Velazquez Y; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital, and Houston Methodist Hospital, Houston, TX., Watanabe A; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital, and Houston Methodist Hospital, Houston, TX., Watanabe N; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital, and Houston Methodist Hospital, Houston, TX., Hoyos V; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital, and Houston Methodist Hospital, Houston, TX., Lulla P; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital, and Houston Methodist Hospital, Houston, TX., Leen AM; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital, and Houston Methodist Hospital, Houston, TX.
Publikováno v: Blood [Blood] 2024 Apr 25; Vol. 143 (17), pp. 1726-1737.
Zobrazit plný text záznamu
5
Akademický článek
Assessment of the cytolytic potential of a multivirus-targeted T cell therapy using a vital dye-based, flow cytometric assay.
Autor: Koukoulias K; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston, TX, United States., Papayanni PG; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston, TX, United States., Jones J; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston, TX, United States., Kuvalekar M; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston, TX, United States., Watanabe A; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston, TX, United States., Velazquez Y; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston, TX, United States., Gilmore S; AlloVir, Waltham, MA, United States., Papadopoulou A; Hematology Department- Hematopoietic Cell Transplantation Unit, Gene and Cell Therapy Center, 'George Papanikolaou' Hospital, Thessaloniki, Greece., Leen AM; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston, TX, United States., Vasileiou S; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston, TX, United States.
Publikováno v: Frontiers in immunology [Front Immunol] 2023 Dec 22; Vol. 14, pp. 1299512. Date of Electronic Publication: 2023 Dec 22 (Print Publication: 2023).
Zobrazit plný text záznamu
6
Akademický článek
Allogeneic, off-the-shelf, SARS-CoV-2-specific T cells (ALVR109) for the treatment of COVID-19 in high-risk patients.
Autor: Vasileiou S; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston, TX. sxvasile@texaschildrens.org., Hill L; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston, TX., Kuvalekar M; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston, TX., Workineh AG; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston, TX., Watanabe A; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston, TX., Velazquez Y; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston, TX., Lulla S; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston, TX., Mooney K; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston, TX., Lapteva N; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston, TX., Grilley BJ; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston, TX., Heslop HE; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston, TX., Rooney CM; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston, TX., Brenner MK; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston, TX., Eagar TN; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston, TX., Carrum G; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston, TX., Grimes KA; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston, TX., Leen AM; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston, TX., Lulla P; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston, TX.
Publikováno v: Haematologica [Haematologica] 2023 Jul 01; Vol. 108 (7), pp. 1840-1850. Date of Electronic Publication: 2023 Jul 01.
Zobrazit plný text záznamu
7
Editorial & Opinion
Longitudinal analysis of the evolution of cellular immunity to SARS-CoV-2 induced by infection and vaccination.
Autor: Vasileiou S; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston. sxvasile@texaschildrens.org., Kuvalekar M; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston., Velazquez Y; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston., Watanabe A; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston., Narula M; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston., Workineh AG; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston., French-Kim M; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston., Chavez AT; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston., Gilmore S; AlloVir, Inc., Waltham., Rooney CM; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston., Leen AM; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston.
Publikováno v: Haematologica [Haematologica] 2023 Jul 01; Vol. 108 (7), pp. 1934-1939. Date of Electronic Publication: 2023 Jul 01.
Zobrazit plný text záznamu
8
Akademický článek
Multi-antigen-targeted T-cell therapy to treat patients with relapsed/refractory breast cancer.
Autor: Hoyos V; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston, TX, USA Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, 1102 Bates Ave, Feigin Center 17th Floor. Houston, TX 77030, USA., Vasileiou S; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston, TX, USA., Kuvalekar M; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston, TX, USA., Watanabe A; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston, TX, USA., Tzannou I; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston, TX, USA., Velazquez Y; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston, TX, USA., French-Kim M; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston, TX, USA., Leung W; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston, TX, USA., Lulla S; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston, TX, USA., Robertson C; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston, TX, USA., Foreman C; Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA., Wang T; Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA., Bulsara S; Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA., Lapteva N; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston, TX, USA., Grilley B; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston, TX, USA., Ellis M; Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA., Osborne CK; Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA., Coscio A; Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA., Nangia J; Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA., Heslop HE; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston, TX, USA., Rooney CM; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston, TX, USA., Vera JF; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston, TX, USA., Lulla P; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston, TX, USA., Rimawi M; Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA., Leen AM; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston, TX, USA.
Publikováno v: Therapeutic advances in medical oncology [Ther Adv Med Oncol] 2022 Jul 15; Vol. 14, pp. 17588359221107113. Date of Electronic Publication: 2022 Jul 15 (Print Publication: 2022).
Zobrazit plný text záznamu
9
Akademický článek
Donor-derived multiple leukemia antigen-specific T-cell therapy to prevent relapse after transplant in patients with ALL.
Autor: Naik S; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston, TX., Vasileiou S; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston, TX., Tzannou I; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston, TX., Kuvalekar M; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston, TX., Watanabe A; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston, TX., Robertson C; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston, TX., Lapteva N; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston, TX., Tao W; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston, TX., Wu M; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston, TX., Grilley B; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston, TX., Carrum G; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston, TX., Kamble RT; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston, TX., Hill L; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston, TX., Krance RA; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston, TX., Martinez C; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston, TX., Tewari P; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston, TX., Omer B; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston, TX., Gottschalk S; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston, TX., Heslop HE; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston, TX., Brenner MK; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston, TX., Rooney CM; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston, TX., Vera JF; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston, TX., Leen AM; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston, TX., Lulla PD; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston, TX.
Publikováno v: Blood [Blood] 2022 Apr 28; Vol. 139 (17), pp. 2706-2711.
Zobrazit plný text záznamu
10
Akademický článek
Clinical effects of administering leukemia-specific donor T cells to patients with AML/MDS after allogeneic transplant.
Autor: Lulla PD; Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX; and., Naik S; Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX; and., Vasileiou S; Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX; and., Tzannou I; Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX; and., Watanabe A; Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX; and., Kuvalekar M; Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX; and., Lulla S; Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX; and., Carrum G; Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX; and., Ramos CA; Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX; and., Kamble R; Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX; and., Hill L; Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX; and., Randhawa J; Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX; and.; Department of Hematology, Houston Methodist Hospital, Houston, TX., Gottschalk S; Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX; and., Krance R; Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX; and., Wang T; Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX; and., Wu M; Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX; and., Robertson C; Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX; and., Gee AP; Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX; and., Chung B; Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX; and.; Department of Hematology, Houston Methodist Hospital, Houston, TX., Grilley B; Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX; and., Brenner MK; Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX; and., Heslop HE; Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX; and., Vera JF; Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX; and., Leen AM; Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX; and.
Publikováno v: Blood [Blood] 2021 May 13; Vol. 137 (19), pp. 2585-2597.
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje